Active, not recruitingPhase 3NCT06091865
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Odronextamab(drug)
- Enrollment
- 904 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- University of California Irvine Medical Center, Orange, California, United States
- University of California (UC) Davis, Sacramento, California, United States
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
- St Vincent Ascension at Peyton Manning Childrens Hospital, Indianapolis, Indiana, United States
- Investigative Clinical Research of Indiana, Noblesville, Indiana, United States
- University of Kentucky, Lexington, Kentucky, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Stony Brook University Hospital, Stony Brook, New York, United States
- Clinical Research Alliance Inc, Westbury, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06091865 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.